The effects of Malassezia in the activation of Interleukin (IL)-23/IL-17 axis in Psoriasis

被引:0
|
作者
Fang, HuaLi [1 ]
Hou, YingDou [2 ]
Zhuang, Hui [3 ]
Wang, ChengHong [1 ]
机构
[1] Yantaishan Hosp, Dept Lab, Yantai 264000, Shandong, Peoples R China
[2] Weihai Stomatol Hosp, Dept Lab, Weihai City 264200, Shandong, Peoples R China
[3] Yantai City Ctr Blood Stn, Dept Lab, Yantai 264003, Shandong, Peoples R China
来源
NEW MICROBIOLOGICA | 2022年 / 45卷 / 02期
关键词
Psoriasis; Malassezia; Interleukin-23/Interleukin-17; axis; ANTIMICROBIAL PEPTIDES; CATHELICIDIN LL-37; EXPRESSION; IL-17;
D O I
暂无
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We explore the association of Malassezia and IL-23/IL-17 axis in the skin lesions of patients with Psoriasis. From October 2018 to October 2020, 202 psoriasis patients were hospitalized in the dermatology department of Yantaishan hospital. The patients' skin lesions were collected, and Malassezia-specific mRNA in the skin lesions was determined. The patients were subdivided into Malassezia high and low distribution groups as per the Malassezia-specific mRNA results. Psoriasis Area and Severity Index (PASI) scores between the two groups were performed. LL-37, IL-23, IL-17A, and tumor necrosis factor alpha (TNF-alpha) expression in the skin lesions of the two groups were determined. Malassezia mRNA and the correlation of LL-37 with inflammatory factors TNF-alpha, IL-23, and IL-17A were determined. The relevance of inflammatory factors, Malassezia infection, and LL-37 content with PASI score were studied. The Malassezia high distribution group was treated with ketoconazole, and the effects of treatment on the PASI score, IL-23, TNF-alpha, and IL-17A were determined. The PASI score, neutrophil, eosinophil, and peripheral blood white blood cell counts, and lgG in the Malassezia high distribution group were significantly higher than in the low distribution group (P < 0.05). IL-23, LL-37, TNF-alpha, and IL-17A levels in the Malassezia high distribution group were significantly higher than in the low distribution group (P < 0.05). Malassezia and LL-37 levels had a moderate positive correlation (R=0.5009, P < 0.0001). Malassezia and LL-37, IL-17A, TNF-alpha, and IL-23 correlated positively. Malassezia, IL-17A, LL37, TNF-alpha, and IL-23 correlated positively with the PASI score of Psoriasis. Ketoconazole therapy inhibited the PASI score, IL-23, TNF-alpha, and IL-17A expressions in patients. Malassezia enhances the progression of Psoriasis through the aberrant activation of the IL-23/IL-17 axis.
引用
收藏
页码:130 / 137
页数:8
相关论文
共 50 条
  • [41] Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis
    Xinwei Wang
    Zhiming Lin
    Qiujing Wei
    Yingjuan Jiang
    Jieruo Gu
    Rheumatology International, 2009, 29 : 1343 - 1347
  • [42] SERUM INTERLEUKIN-17 (IL-17) AND IL-23 IN LUNG CANCER PATIENTS
    Cam, C.
    Karagoz, B.
    Muftuoglu, T.
    Bilgi, O.
    Ozgun, A.
    Tuncel, T.
    Emirzeoglu, L.
    Celik, S.
    Top, C.
    RESPIROLOGY, 2014, 19 : 164 - 164
  • [43] IL-17 Blockade in Psoriasis
    Burkett, Patrick R.
    Kuchroo, Vijay K.
    CELL, 2016, 167 (07) : 1669 - 1669
  • [44] The role of IL-17 in psoriasis
    Malakouti, Mona
    Brown, Gabrielle Elena
    Wang, Eva
    Koo, John
    Levin, Ethan C.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2015, 26 (01) : 41 - 44
  • [45] Loss of epidermal phospholipase C δ1 results in IL-23/IL-17 axis activation and granulocytosis
    Kanemaru, K.
    Nakamura, Y.
    Fukami, K.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2012, 132 : S16 - S16
  • [46] Anti IL-17 in psoriasis
    Ly, Karen
    Smith, Mary P.
    Thibodeaux, Quinn
    Reddy, Vidhatha
    Liao, Wilson
    Bhutani, Tina
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2019, 15 (11) : 1185 - 1194
  • [47] IL-17 inhibitors for psoriasis
    Paek, So Yeon
    Frieder, Jillian
    Kivelevitch, Dario
    Menter, M. Alan
    SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2018, 37 (03) : 148 - 157
  • [48] Skin dysbiosis promotes autoimmune inflammation via neutrophil activation and the IL-23/IL-17 axis
    Terui, H.
    Yamasaki, K.
    Wada-Irimada, M.
    Onodera-Amagai, M.
    Hatchome, N.
    Mizuashi, M.
    Yamashita, R.
    Kawabe, T.
    Ishii, N.
    Abe, T.
    Asano, Y.
    Aiba, S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (12) : S182 - S182
  • [49] Targeting IL-17 in psoriasis
    Juan Carlos López
    Nature Medicine, 2012, 18 (5) : 671 - 671
  • [50] How to choose between IL-17 inhibitors and IL-23 inhibitors for psoriasis
    Amin, Mina
    Lee, Erica B.
    Wu, Jashin J.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2019, 30 (04) : 374 - 375